Testing effectiveness (Phase 2)Ended earlyNCT03809663
What this trial is testing
A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis
Who this might be right for
Atopic Dermatitis
Amgen 251